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HEM1 deficiency disrupts mTORC2 and F-actin control
in inherited immunodysregulatory disease
Sarah A. Cook1*, William A. Comrie1,2*, M. Cecilia Poli3,4,5, Morgan Similuk6, Andrew J. Oler7,
Aiman J. Faruqi1, Douglas B. Kuhns8, Sheng Yang9, Alexander Vargas-Hernández3,4,
Alexandre F. Carisey3,4, Benjamin Fournier10,11, D. Eric Anderson12, Susan Price13,
Margery Smelkinson14, Wadih Abou Chahla15, Lisa R. Forbes3,4, Emily M. Mace16, Tram N. Cao3,4,
Zeynep H. Coban-Akdemir17,18, Shalini N. Jhangiani18,19, Donna M. Muzny18,19, Richard A. Gibbs17,18,19,
James R. Lupski17,18,19, Jordan S. Orange16, Geoffrey D. E. Cuvelier20, Moza Al Hassani21,
Nawal Al Kaabi21, Zain Al Yafei21, Soma Jyonouchi22,23, Nikita Raje24,25, Jason W. Caldwell26,
Yanping Huang27,28, Janis K. Burkhardt27, Sylvain Latour10,11, Baoyu Chen9, Gehad ElGhazali21,
V. Koneti Rao13, Ivan K. Chinn3,4, Michael J. Lenardo1†
Immunodeficiency often coincides with hyperactive immune disorders such as autoimmunity,
lymphoproliferation, or atopy, but this coincidence is rarely understood on a molecular level. We describe
five patients from four families with immunodeficiency coupled with atopy, lymphoproliferation, and
cytokine overproduction harboring mutations in NCKAP1L, which encodes the hematopoietic-specific HEM1
protein. These mutations cause the loss of the HEM1 protein and the WAVE regulatory complex (WRC) or
disrupt binding to the WRC regulator, Arf1, thereby impairing actin polymerization, synapse formation, and
immune cell migration. Diminished cortical actin networks caused by WRC loss led to uncontrolled cytokine
release and immune hyperresponsiveness. HEM1 loss also blocked mechanistic target of rapamycin complex
2 (mTORC2)–dependent AKT phosphorylation, T cell proliferation, and selected effector functions, leading
to immunodeficiency. Thus, the evolutionarily conserved HEM1 protein simultaneously regulates filamentous
actin (F-actin) and mTORC2 signaling to achieve equipoise in immune responses.
I
nborn errors of immunity (IEIs) can affect
global cellular regulatory systems (1). The
mechanistic target of rapamycin complex 1
(mTORC1) and mTORC2 are global regu-
lators of metabolism and cell signaling.
mTORC2, comprising the mTOR, RICTOR,
mSIN1, mLST8, PROTOR1 and PROTOR2
(PROTOR1/2), and DEPTOR proteins, activates
AGC kinases downstream of phosphoinositide
3-kinase (PI3K) to promote T cell survival, pro-
liferation, and differentiation (2–5). Similarly,
actin is a global regulator of cellular behavior
and immune synapse (IS) formation (6, 7). Sig-
nals activating the WAVE regulatory complex
(WRC),which contains CYFIP1/2,HEM1/2, ABI1/
2/3, HSPC300, andWAVE1/2/3, control the
dynamics of Arp2/3-mediated branched fila-
mentous actin (F-actin) nucleation and poly-
merization. In theWRC,HEM1/2 andCYFIP1/2
form a membrane-associated scaffold support-
ing the ABI1/2, HSPC300, and WAVE1/2/3
proteins and are directly activated by the small
guanosine triphosphatases (GTPases) Rac1 and
Arf1, although the Arf1 binding site is uncertain
(8, 9) (Fig. 1). Whether the WRC regulates the
cortical actin network (CAcN) is unknown
(6–12). Mutations affecting actin regulatory
proteins underlie immunodeficiencies (table
S1), but none have been reported yet for WRC
components (13).
We investigated five patients from four un-
related families with recurrent bacterial and
viral skin infections, severe respiratory tract
infections leading to pneumonia and bron-
chiectasis (Fig. 1, A and B, left panels, and fig.
S1A), and poor specific antibody responses
(Fig. 1B, right panel, and table S2). Paradox-
ically, these patients also exhibited atopic and
inflammatory disease alongside chronic hep-
atosplenomegaly and lymphadenopathy, some-
times with elevated immunoglobulin E (IgE) or
IgG and autoimmune manifestations (Fig. 1B;
fig. S1, B and C; and tables S2 and S3). FoxP3+
T regulatory cells were normal (fig. S1D). All
five patients harbored biallelicNCKAP1Lmuta-
tions encoding missense variants in HEM1, the
hematopoietic-specific member of the WRC
(Fig. 1, A and C, and table S4). The amino acid
substitutions affected conserved residues that
were not homozygous in the Genome Aggre-
gation Database (gnomAD) or internal data-
bases and were bioinformatically predicted to
be damaging (fig. S2, A and B) (14). The altered
residues clustered within the quaternary struc-
ture of the WRC near the distal Rac1-binding
site located on CYFIP1/2 (fig. S2, A to D),
which we call the HEM1 regulatory site (HRS).
The human immune phenotype differs from
the lymphopenia, neutrophilia, or bone mar-
row failure observed in HEM1-deficient mice
(12, 15, 16).
Biochemical analyses showed that patients
1.1, 2.1, 2.2, and 4.1 lost HEM1, CYFIP1, and
WAVE2, which indicatesWRC destabilization,
whereas patient 3.1 expressed normal levels
of WRC proteins (Fig. 1D and fig. S3, A to C).
Moreover, theHEM1 substitutions in patients
1.1 and 2.1, but not in patient 3.1, reduced
affinity for WAVE2 (Fig. 1E and fig. S3D). The
WRC could be restored inNCKAP1L CRISPR-
Cas9 knockout (HEM1-KO) Jurkat cells by
wild-type and patient 3.1 HEM1 but less so
by the patient 1.1 and 2.1 variants (fig. S3E).
Immunoprecipitation–mass spectrometry (IP-
MS) showed that the Met371→Val (M371V)
HEM1 variant (patient 3.1) maintained asso-
ciation with HEM1- and WAVE2-interacting
proteins (fig. S4 and table S5). We therefore hy-
pothesized that M371V disrupted the activation
by either Rac1 or Arf1, the small GTPases that
activate the WRC. By reconstituting the WRC
in vitrowith recombinant proteins (containing
HEM2with the equivalentM373V substitution,
but notHEM1, which had an insufficient yield),
we observed that the HEM2-M373V protein in-
teracted poorly with GST-Arf1 and could not
promote F-actin polymerization upon stimu-
lation with an Arf1-Rac1 dimer (Fig. 1F and
fig. S3, F to H). Thus, the Met371/373 residues
RESEARCH
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located in the HRS of HEM1/2 are crucial for
Arf1 binding and WRC activation, which is
analogous to binding of Rac1 to CYFIP1/2 (8).
Therefore, the patient HEM1 mutants either
destabilize theWRCor disrupt its Arf1-mediated
activation (fig. S2E).
We observed that interleukin-2 (IL-2) stim-
ulation caused patient and HEM1-knockdown
cells to hypersecrete perforin and granzymes
and hyperproliferate in response to IL-2 (Fig.
2, A and B, and fig. S5, A, B, and E). Proximal
IL-2 signaling was normal, which implies that
downstream processes, such as CAcN control
of granule release, might have been affected
(fig. S6) (17–19). We found evidence for an ab-
normal CAcN because patient cells displayed
reduced cortical F-actin and aberrant mem-
brane spikes and puncta caused by unregulated
formin and WASp, respectively (Fig. 2C and
movie S1) (20). We also observed defective cell
spreading and lamellipodia (fig. S5C). Patient
T cells expressed higher levels of surface CD107a
(LAMP1), which indicates increased granule
membrane fusion, especially after phorbol
myristate acetate and ionomycin–induced
degranulation (Fig. 2D and fig. S5D). Exper-
imental reduction of HEM1 in primary T cells
and NKL cells also increased the release of
cytokines and granule contents, CD107a ex-
pression, or both (fig. S5, E to H). Three-
dimensional imaging revealed a diminished
CAcN and a notable accumulation of lytic
granules at the IS of patient cells (Fig. 2E).
Latrunculin A (LatA), which depolymerizes
F-actin, increased exocytosis-based CD107a sur-
face expression and the release of granzymes A
and B in a dose-dependent manner (Fig. 2D,
bottom, and fig. S5, I and J). Thus, the WRC
containing HEM1 enables the CAcN to restrain
excessive degranulation and granule release by
Tcells. Constitutive cytokine releasewasblocked
by a Jak inhibitor (fig. S5E).
We next explored other F-actin functions
using live-cell imaging of the T cell IS and
found that patient cells and HEM1-KO Jurkat
cells reconstituted with mutant HEM1 alleles
cannot form symmetrical and stable synaptic
contacts with the coverslip (movies S1 and S2)
(20).We also observed abnormal formin spikes,
WASp-mediated puncta, and defective lamelli-
podia. Because lamellipodia guide cellmigration,
Cook et al., Science 369, 202–207 (2020) 10 July 2020 2 of 6
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Fig. 1. Immunodysregulatory disorder caused by genetic HEM1
deficiency. (A) Patient (Pt) pedigrees showing recessive inheritance
of disease and HEM1 amino acid substitutions. Red symbols indicate
deceased affected siblings of unknown genotype. N/D, not determined.
(B) Chest computed tomography (CT) scans showing ground glass
opacity and pneumonia (red outline) in Pt 1.1 (upper left) and
bronchiectasis (red arrow) in Pt 2.2 (bottom left). Key shared clinical
features are also noted (right). (C) Structural location of patient
variants in HEM1 in the WRC (Protein Data Bank: 3P8C; PubMed ID:
21107423). HRS, HEM1 regulatory site. (D) Immunoblot of WRC
components in lysates derived from Pt and normal control (NC)
CD4+ (left) and CD8+ (right) T cell blasts. (E) Quantification of WAVE2
coimmunoprecipitated (co-IP) by wild-type (WT) or mutant HEM1-Flag
constructs in six independent experiments. Statistical analysis was
performed using a one-sample t test. (F) Pyrene-actin polymerization
assay with WRC230VCA containing HEM2 WT or M373V, with or
without activation by a Rac1-Arf1 heterodimer preloaded with GMPPNP.
(Inset) Coomassie blue–stained gel showing GST-Arf1 pull-down of
WRC230VCA containing HEM2 WT or M373V and Rac1 (Q61L/P29S).
Data are representative of four independent experiments. **P ≤ 0.01;
***P ≤ 0.001. Single-letter abbreviations for the amino acid residues
are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His;
I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser;
T, Thr; V, Val; W, Trp; and Y, Tyr.
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we evaluated spontaneous T cell and neutrophil
migration (21, 22). We found that patient T cells
exhibited defective membrane ruffling; loss
of lamellipodial extensions; decreased F-actin
density at the leading edge with abnormal
puncta, spikes, and blebs; and reducedmigratory
velocity (fig. S7, A and B, and movie S3).
Similarly, patient neutrophils migrating in
chemokine gradients exhibited reduced veloc-
ity and directional persistence, unusual elonga-
tion, and misdirected competing leading edges
(Fig. 3, A and B; movie S4; and fig. S7C). In
patients for whom we had sufficient samples,
we founddecreasednatural killer (NK) cell abun-
dance along with defective F-actin accumula-
tion at the IS and a corresponding defect in
conjugate formation (Fig. 3, C and D, and fig.
S7E). Additionally, HEM1-KONKL clones dis-
played reduced effector function after stimu-
lation (fig. S7, F and G).
We also found abnormal T cell activation
manifested by reduced CD69 and CD25 ex-
pression, blunted proliferation, and decreased
IL-2 and tumor necrosis factor (TNF) produc-
tion (Fig. 3, E to G, and fig. S9, A and B). Ad-
ditionally, patient T cells had defective integrin
activationwith lower soluble ICAM-1 binding,
though adherence to immobilized ICAM-1 was
largely intact, which indicates a defect in
integrin affinity maturation. Notably, we found
that CD8+ T cell cytotoxicity and the release
of granzyme A, granzyme B, and perforin were
normal (fig. S8, A to C, and fig. S9, C and D)
(21, 23, 24). Proliferation and cytokine defects
were recapitulatedby short hairpinRNA(shRNA)
knockdown of HEM1 (Fig. 3, H and I).
Despite the IS abnormalities, proximal T cell
receptor (TCR) signaling events in HEM1-
deficient patient cells were normal (fig. S10, A
to C) (21). Nevertheless, we found that both
patient and HEM1-knockdown T cells showed
defective TCR-induced phosphorylation of
a well-known substrate of the mTORC2 com-
plex, AKT (protein kinase B), at Ser473 (Fig. 4A
and fig. S11, A to C) (25). Phosphorylation of
mTORC2-independent targets, including AKT
Thr308 and ribosomal protein S6 Ser235/236 and
Ser240/244, was moderately reduced in patient
cells, but these defects were not recapitulated
by HEM1 knockdown (Fig. 4B and fig. S11, C
and D). Immunoblotting showed decreased
phosphorylation of AKT Ser473 as well as de-
creased Ser21 of the downstream AKT sub-
strate, glycogen synthase kinase (GSK) 3a
Cook et al., Science 369, 202–207 (2020) 10 July 2020 3 of 6

























Pan T cell blasts
CD4+ T cell blasts
CD107a

















D         
Perforin
















































































Fig. 2. HEM1 is essential for regulating cortical actin and granule release.
(A) Release of granzymes (Gzm) A and B or perforin from Pt or control (Ctrl)
CD8+ T cell blasts after 18 hours of IL-2 stimulation in international units (I.U.) in
three independent experiments. (B) Flow cytometric histograms measuring
proliferation of rested CD4+ T cell blasts from a normal control (Ctrl) or patient 1.1
(Pt 1.1) measured by carboxyfluorescein succinimidyl ester (CFSE) dilution after
IL-2 restimulation for 96 hours. (C) (Left) Ctrl or Pt 1.1 CD4+ T cell blasts spreading
on coverslips coated with anti-CD3, anti-CD28, and ICAM-1 (1 mg/ml each),
stained with phalloidin, and pseudocolored for F-actin. (Right) F-actin was
quantified in three experiments. Red arrows indicate formin-mediated spikes,
and white arrows indicate WASp-mediated actin puncta. Scale bar, 4 mm.
(D) Surface CD107a on Ctrl and Pt 3.1 CD4+ T cell blasts after 1 hour of phorbol
myristate acetate (PMA)/ionomycin (I) stimulation (top) or stimulated pan T cells
with 1 mM latrunculin A (LatA) (bottom). (E) (Left) Side view of perforin granules
pseudocolored by Z-position relative to the cell center in Ctrl or Pt 1.1 CD8+ T cell
blasts. (Middle) Corresponding 90° forward rotation top views of F-actin (red) and
perforin (green). Red arrows indicate lamellipodial F-actin density. Scale bar,
2 mm. (Right) Mean ratios of granules in the bottom half to top half of the cell,
quantified in at least 30 cells per sample. Bars represent means ± SEM (control,
n = 6; patient, n = 3). Data represent at least three repeat experiments. Statistical
analyses for (A), (C), and (E) were performed using a t test without assuming
equal variance. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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(Fig. 4C). TCR-induced AKT Ser473 in T cells
could be blocked by an mTOR catalytic in-
hibitor (Ku0063794), whereas inhibition of the
actin network by LatA moderately enhanced
AKT Ser473 phosphorylation. Thus, the AKT
Ser473 phosphorylation defect appears to be
independent of HEM1 regulation of the CaCN
(fig. S11, E and F).
To investigate howHEM1 regulates the phos-
phoinositide 3-kinase (PI3K)–AKT–mTORC2
pathway, we searched our IP-MS datasets and
found that several mTORC2 components—
including mTOR and RICTOR, the key scaf-
folding protein of mTORC2—were precipitated
byHEM1 but notWAVE2 (fig. S4, fig. S12A, and
table S5). This observation suggested the exis-
tence of a pool ofHEM1outside of theWRC that
interacts with and regulates mTORC2 (22).
Testing HEM1-Flag (wild-type, P359L, and
M371V), Flag–green fluorescent protein (GFP),
myc-RICTOR, or WAVE2 from 293T cells, we
observed that HEM1, but not WAVE2, specif-
ically coimmunoprecipitated with RICTOR
(Fig. 4D and fig. S12, A and B). Notably, the
P359LHEM1 is strongly associatedwithRICTOR,
which suggests that the interaction occurs
when HEM1 is not in complex with the WRC.
Knockdown of RICTOR in CD4+ T cells im-
paired proliferation and cytokine secretion
(Fig. 4, E and F, and fig. S12D). Chemical in-
hibitors of the PI3K, AKT, or mTOR kinases
also abrogated T cell proliferation and IL-2
and TNF secretion (fig. S12, E and F). Notably,
specific inhibition of mTORC1 with rapamy-
cin had little effect compared with inhibition
of both complexes with an mTOR catalytic
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Fig. 3. HEM1 loss causes immunodeficiency by abnormal immune cell
behavior and activation. (A) Single frame from movie S4 showing healthy
Ctrl or Pt 1.1 neutrophils migrating in a gradient (bottom has the greatest
concentration) of N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF).
Scale bar, 20 mm. (B) Displacement velocity (top) and net directed distance
(Dist.) (bottom) in arbitrary units (A.U.) of 10 randomly selected Ctrl or
Pt 1.1 neutrophils migrating in chemoattractant gradients. (C) Percentage of
NK cells in four peripheral blood samples. (D) Photomicrographs of
immunological synapses between K562 target cells (orange outline) and
NK cells (white outline) stained with phalloidin for F-actin and WAVE2
antibody. White boxes indicate area of synapse. Scale bar, 5 mm. (E) CD69 and
CD25 up-regulation on Ctrl or Pt 1.1 naïve CD4+ T cells after stimulation
with immobilized anti-CD3/28 (1 mg/ml each). Max, maximum. (F) Cell trace
violet (CTV) proliferation plots of cells as in (E), stimulated for 5 days.
(G) IL-2 and TNF secretion by CD4+ or CD8+ T cell blasts after restimulation
for 36 hours with immobilized anti-CD3/28 and ICAM-1 (1 mg/ml each) in
three independent experiments. (H) CTV plots of naive CD4+ T cells
transduced with empty vector (EV) or small hairpin RNA against HEM1
(sh-HEM1), stimulated on immobilized ICAM-1/anti-CD28 (1 mg/ml each) and
the indicated dose of anti-CD3. (I) IL-2 and TNF secretion by CD4+ T cell
blasts transduced with EV, sh-HEM1-1, or sh-HEM1-2 and stimulated as in (H).
Neutrophil migration was analyzed for two independent donors; otherwise,
data represent at least four independent trials of each assay. Statistical
analyses for (B), (C), and (G) were performed using a t test without assuming
equal variance. Statistical analysis for (I) was performed using a Wilcoxon
matched-pairs signed-rank test. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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inhibitor, which suggests that mTORC2, but
not mTORC1, is required. However, mTOR
inhibition had little effect on the secretion of
perforin and granzymes or on CD69 and CD25
up-regulation, essentially phenocopying the
defects observed in patient cells (fig. S12, G
to I). Thus, HEM1 plays an additional role in
human T cells outside of the WRC as an up-
stream regulator of mTORC2 enzymatic ac-
tivity (Fig. 4G).
Previous studies have shown that individual
WRC components can have noncanonical roles
in cellular processes beyond actin filament nu-
cleation and that HEM1/2 exists, and likely
functions, outside of theWRC complex (11, 22).
We now show that in human patients with im-
munodeficiency and immune hyperactivation,
the loss-of-functionmutations inNCKAP1L, the
gene encodingHEM1, disruptWRC-mediated
actin polymerization and abrogate mTORC2
activation of AKT. The resulting autosomal
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Fig. 4. HEM1 associates with RICTOR and governs mTORC2 activation.
(A) Phospho-flow cytometry of purified CD4+ T cell blasts from Ctrl or
Pt (top row) or EV transduced or sh-HEM1 knockdown cells (bottom row) for
AKT phosphorylated on Ser473 (pAKT S473). Cells were stimulated for
10 min with anti-CD28 and ICOS (1 mg/ml each) and the indicated dose of
anti-CD3. (B) Mean fluorescence intensity (MFI) of pAKT S473 or AKT
pAKT T308 in EV or sh-HEM1 CD4+ T cell blasts stimulated as in (A) in
six independent experiments. US, unstimulated; ns, not significant.
(C) Immunoblot of Ctrl or Pt CD4+ T cell blasts, or healthy CD4+ T cell blasts
cells transduced with EV or sh-HEM1. Cells were rested and restimulated
with ICAM-1 and anti-CD28 (1 mg/ml each) and the indicated dose of anti-CD3.
(D) Flag and RICTOR IP from 293T cells transduced with myc-RICTOR and
either Flag-tagged GFP or Flag-tagged HEM1 (WT or mutant) and blotted.
(E) CTV proliferation plots of naïve CD4+ T cells transduced with EV or shRNA
directed against RICTOR (sh-RIC). (F) Cytokine secretion by control and
RICTOR knockdown (sh-RIC) CD4+ T cell blasts after 18-hour restimulation in
five independent experiments. (G) Provisional model of HEM1 independently
regulating WRC- and mTORC2-mediated functions. Statistical analyses for
(B) and (F) were performed using a Wilcoxon matched-pairs signed-rank test.
*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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recessive IEI affects multiple hematopoietic
lineages and leads to bacterial and viral in-
fections, atopic disease, autoimmunity, cyto-
kine overproduction, and lymphoproliferative
disease. We demonstrate that HEM1 and the
WRCmaintain the CAcN, which restricts cyto-
kine secretion and lytic granule release. We
also show that HEM1 plays a key binding role
in Arf1-mediated WRC activation. Our find-
ings suggest a broader effect of genetic HEM1
deficiency on the cytokine repertoire and cellu-
lar effector function that should be addressed
in future work. Finally, we identify an interac-
tion betweenHEM1 andRICTOR that is essen-
tial for mTORC2 regulation. HEM1 may have
escaped detection in previous RICTOR precip-
itation experiments because the interaction
appears to be weak and because commonly
used 293T cells do not express the hemato-
poietically restrictedHEM1.Weposit thatHEM1
independently coordinatesWRC-mediated actin
nucleation and mTORC2 catalytic activity in
response to signals that activate both protein
complexes—such as PI3K, Arf1, and Rac1—
during T cell activation and possibly during B
and NK cell activation. These data could ex-
plain how mTORC2 is activated downstream
of actin-generated membrane tension and can
negatively regulate the WRC (26). Because
mTORC2 exerts similar roles in all lympho-
cytes, and because their activation involves
actin-dependent regulation, it is likely that
B and NK cell abnormalities contribute to
immunopathology in the HEM1-deficient pa-
tients (27–29). Our study elucidates a human
congenital disorder caused by loss of HEM1
and highlights potential routes for immuno-
logical therapy.
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disease phenotype. By linking these interactions to immune function, this work suggests potential targets for future
actin and granule release in T cells and also interacted with a key metabolic signaling complex contributing to the 
along with enhanced allergic and autoimmune disorders. HEM1 was found to be required for the regulation of cortical
encoding the WRC component HEM1. These patients presented with recurrent infections and poor antibody responses, 
 studied five patients from four unrelated families who harbor missense variants of the geneet al.established. Cook 
other actin-regulatory proteins modulate human immune responses, the precise role for the WRC has not yet been 
The WAVE regulatory complex (WRC) is a multiunit complex that regulates actin cytoskeleton formation. Although
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